Haemonetics Corp Stock Research

Market Summary

USD83.21+0.33

Market Closed

0.40%

HAE Stock Price

HAE RSI Chart

HAE Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

36.38

Price/Sales (Trailing)

3.72

EV/EBITDA

16.67

Price/Free Cashflow

25.77

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

10.99%

Return on Equity

12.34%

Return on Assets

5.1%

Free Cashflow Yield

3.88%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

17.53%

Revenue Q/Q

2.63%

HAE Earnings

Earnings (TTM)

115.4M

Earnings Y/Y

201.64%

Earnings Q/Q

-10.81%

Price Action

52 Week Range

58.2391.39

(Low)(High)

Last 7 days

-1.1%

Last 30 days

1.1%

Last 90 days

5.5%

Trailing 12 Months

33.6%

HAE Financial Health

Current Ratio

3.11

HAE Investor Care

Buy Backs (1Y)

1.32%

Diluted EPS (TTM)

2.24

Peers (Alternatives to Haemonetics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	110.8B	19.0B	-8.78%	16.43%	46.98	6.01	8.73%	30.37%
ISRG	107.5B	6.4B	4.05%	37.44%	81.96	16.72	8.89%	-20.19%
BSX	74.1B	13.0B	-0.08%	27.20%	106.12	5.84	7.26%	-32.95%
BDX	71.3B	18.8B	-6.73%	-3.13%	44.09	3.79	-1.96%	-15.83%
EW	49.7B	5.5B	-6.18%	-16.80%	33.38	9.03	2.68%	-3.23%
MID-CAP
SWAV	7.2T	557.2M	-1.64%	66.40%	82.2K	16.8K	86.42%	730.06%
PEN	11.7B	884.6M	7.85%	115.97%	1.8K	13.2	13.08%	200.12%
GMED	5.9B	1.1B	-8.20%	-19.98%	34.14	5.75	11.20%	53.04%
IRTC	3.6B	430.0M	-11.89%	-12.63%	-34.73	8.45	26.13%	15.73%
TNDM	1.7B	794.7M	-29.15%	-60.56%	-8.43	2.16	7.73%	-3556.34%
SMALL-CAP
ATEC	1.6B	389.0M	-3.76%	82.19%	-10.63	4.18	44.08%	6.96%
SILK	1.2B	150.7M	-30.80%	0.49%	-21.65	7.87	40.31%	1.80%
AVNS	1.1B	814.3M	-20.14%	-16.22%	24.47	1.34	6.96%	121.89%
CSII	839.3M	239.8M	0.70%	0.15%	-22.16	3.5	-4.74%	-31.15%

Financials for Haemonetics

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	4.2%	1,129	1,084	1,026	993	953
Gross Profit	3.5%	595	575	540	506	-
Operating Expenses	2.8%	455	443	430	425	-
S&GA Expenses	3.9%	371	357	341	340	-
R&D Expenses	5.9%	48.00	45.00	45.00	47.00	-
EBITDA	4.8%	218	208	187	168	-
EBITDA Margin	0.6%	0.19*	0.19*	0.18*	0.17*	-
Earnings Before Taxes	9.6%	124	113	92.00	64.00	-
EBT Margin	5.1%	0.11*	0.10*	0.09*	0.06*	-
Interest Expenses	-	6.00	-	-	-	-
Net Income	11.3%	96.00	86.00	68.00	43.00	-
Net Income Margin	6.8%	0.08*	0.08*	0.07*	0.04*	-
Free Cahsflow	10.1%	128	116	88.00	76.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	3.0%	1,935	1,878	1,865	1,821	1,860
Current Assets	9.0%	770	706	716	688	756
Cash Equivalents	27.0%	284	224	241	215	259
Inventory	1.4%	259	256	255	278	293
Net PPE	-0.7%	311	313	308	288	258
Goodwill	0.0%	466	466	465	466	467
Current Liabilities	11.0%	252	227	262	180	442
LT Debt, Current	18.4%	12.00	10.00	58.00	7.00	214
LT Debt, Non Current	-0.4%	754	757	760	763	559
Shareholder's Equity	5.4%	818	776	729	770	749
Retained Earnings	13.1%	253	224	204	222	202
Additional Paid-In Capital	1.2%	595	587	564	580	572
Shares Outstanding	0.0%	50.00	50.00	51.00	51.00	51.00

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	4.4%	273	261	260	216	172
Share Based Compensation	8.3%	26.00	24.00	23.00	23.00	24.00
Cashflow From Investing	10.3%	-143	-160	-139	-128	-86.34
Cashflow From Financing	6.7%	-100	-107	-59.88	-37.51	-15.75
Buy Backs	-25.0%	75.00	100	100	0.00	-

Risks for HAE

What is the probability of a big loss on HAE?

80.4%

Probability that Haemonetics stock will be more than 20% underwater in next one year

53.1%

Probability that Haemonetics stock will be more than 30% underwater in next one year.

28.1%

Probability that Haemonetics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HAE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Haemonetics was unfortunately bought at previous high price.

Drawdowns

Returns for HAE

Cumulative Returns on HAE

7.1%

10-Year Cumulative Returns

16.8%

7-Year Cumulative Returns

-1.7%

5-Year Cumulative Returns

-8.3%

3-Year Cumulative Returns

What are the long-term rolling returns for HAE?

FIve years rolling returns for Haemonetics.

Annualized Returns

Which funds bought or sold HAE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	ROYCE & ASSOCIATES LP	added	2.22	4,898,060	69,820,600	0.70%
2023-05-23	Toroso Investments, LLC	added	10.49	72,000	516,000	0.01%
2023-05-22	American Trust	sold off	-100	-207,636	-	-%
2023-05-22	AMERIPRISE FINANCIAL INC	added	3.22	3,014,030	38,085,000	0.01%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	21.13	1,111,000	5,161,000	0.01%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	unchanged	-	210,000	8,022,000	0.01%
2023-05-18	JPMORGAN CHASE & CO	added	16.11	2,672,000	14,721,000	-%
2023-05-17	Advisory Services Network, LLC	added	2.59	1,687	22,922	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	added	76.53	635,151	1,360,640	0.01%
2023-05-17	Thrivent Financial for Lutherans	reduced	-1.23	42,000	1,102,000	-%

Latest Funds Activity

Are funds buying HAE calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own HAE

No. of Funds

Haemonetics News

Schedule 13G FIlings of Haemonetics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	capital research global investors	11.8%	5,956,064	SC 13G/A
Feb 09, 2023	vanguard group inc	10.36%	5,242,836	SC 13G/A
Feb 06, 2023	wellington management group llp	7.97%	4,034,753	SC 13G/A
Jan 26, 2023	blackrock inc.	11.7%	5,898,620	SC 13G/A
Jan 20, 2023	blackrock inc.	11.7%	5,898,620	SC 13G/A
Apr 08, 2022	capital research global investors	10.7%	5,452,006	SC 13G
Feb 14, 2022	neuberger berman group llc	7.59%	3,876,521	SC 13G/A
Feb 11, 2022	capital research global investors	4.0%	2,049,133	SC 13G/A
Feb 10, 2022	vanguard group inc	9.55%	4,880,936	SC 13G/A
Feb 10, 2022	wellington management group llp	10.83%	5,537,538	SC 13G/A

HAE Fair Value

Recent SEC filings of Haemonetics

View All Filings

Date Filed	Form Type	Document
May 22, 2023	10-K	Annual Report
May 19, 2023	4	Insider Trading
May 19, 2023	4	Insider Trading
May 19, 2023	4	Insider Trading
May 19, 2023	4	Insider Trading
May 19, 2023	4	Insider Trading
May 19, 2023	4	Insider Trading
May 17, 2023	4	Insider Trading
May 17, 2023	4	Insider Trading
May 17, 2023	4	Insider Trading

Latest Insider Trading transactions for HAE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-18	Miller Laurie A.	sold (taxes)	-7,500	83.34	-90.00	svp, human resources
2023-05-18	Basil Michelle L	sold (taxes)	-295,107	83.34	-3,541	evp and general counsel
2023-05-18	Strong Stewart W	sold (taxes)	-90,590	83.34	-1,087	president, global hospital
2023-05-18	Simon, Christopher	sold (taxes)	-319,942	83.34	-3,839	president & ceo
2023-05-18	Lingamneni Anila	sold (taxes)	-115,426	83.34	-1,385	evp, chief technology officer
2023-05-18	Llorens Josep	sold (taxes)	-118,593	83.34	-1,423	evp, global manufacturing
2023-05-16	Basil Michelle L	sold (taxes)	-39,787	89.21	-446	evp and general counsel
2023-05-16	Simon, Christopher	sold (taxes)	-141,487	89.21	-1,586	president & ceo
2023-05-16	Lingamneni Anila	sold (taxes)	-28,368	89.21	-318	evp, chief technology officer
2023-05-16	Strong Stewart W	sold (taxes)	-22,302	89.21	-250	president, global hospital

About Haemonetics

Christopher A. Simon

www.haemonetics.com

2710

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Income Statement

2023-04-01

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Apr. 01, 2023	Apr. 02, 2022	Apr. 03, 2021
Income Statement [Abstract]
Net revenues	$ 1,168,660	$ 993,196	$ 870,463
Cost of goods sold	553,563	487,694	472,625
Gross profit	615,097	505,502	397,838
Operating expenses:
Research and development	50,131	46,801	32,857
Selling, general and administrative	376,675	340,140	275,216
Amortization of acquired intangible assets	32,640	47,414	32,830
Gains on divestitures and sale of assets	(382)	(9,603)	(32,812)
Total operating expenses	459,064	424,752	308,091
Operating income	156,033	80,750	89,747
Interest and other expense, net	(14,630)	(17,121)	(16,834)
Income before provision (benefit) for income taxes	141,403	63,629	72,913
Provision (benefit) for income taxes	26,002	20,254	(6,556)
Net income	$ 115,401	$ 43,375	$ 79,469
Net income per share - basic (in dollars per share)	$ 2.27	$ 0.85	$ 1.57
Net income per share - diluted (in dollars per share)	$ 2.24	$ 0.84	$ 1.55
Weighted average shares outstanding
Basic (in shares)	50,783	51,047	50,688
Diluted (in shares)	51,420	51,353	51,292

HAE Balance Sheet

2023-04-01

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 01, 2023	Apr. 02, 2022
Current assets:
Cash and cash equivalents	$ 284,466	$ 259,496
Accounts receivable, less allowance for credit losses of $4,932 at April 1, 2023 and $2,475 at April 2, 2022	179,142	159,376
Inventories, net	259,379	293,027
Prepaid expenses and other current assets	46,735	44,132
Total current assets	769,722	756,031
Property, plant and equipment, net	310,885	258,482
Intangible assets, less accumulated amortization of $417,422 at April 1, 2023 and $376,552 at April 2, 2022	275,771	310,261
Goodwill	466,231	467,287
Deferred tax asset	5,241	4,468
Other long-term assets	106,975	63,205
Total assets	1,934,825	1,859,734
Current liabilities:
Notes payable and current maturities of long-term debt	11,784	214,148
Accounts payable	63,929	58,371
Accrued payroll and related costs	64,475	48,540
Other current liabilities	111,628	121,207
Total current liabilities	251,816	442,266
Long-term debt, net of current maturities	754,102	559,441
Deferred tax liability	36,195	28,727
Other long-term liabilities	74,715	79,876
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,448,519 shares at April 1, 2023 and 51,124,240 shares at April 2, 2022	504	511
Additional paid-in capital	594,706	572,476
Retained earnings	253,168	202,391
Accumulated other comprehensive loss	(30,381)	(25,954)
Total stockholders’ equity	817,997	749,424
Total liabilities and stockholders’ equity	$ 1,934,825	$ 1,859,734